Company news

Myriad Genetics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter

November 8, 2020

Myriad Genetics to Announce Quarterly Financial Results on November 9, 2020

November 3, 2020

Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests

October 14, 2020

Myriad Genetics Expands Board of Directors with New Member

September 9, 2020

Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors

August 12, 2020

Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020

August 5, 2020

Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test

July 28, 2020

Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®

July 27, 2020

Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.

July 21, 2020

Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction

July 6, 2020

Myriad Announces Partnership with OptraHEALTH® to Deliver “Gene™” a New AI Based Information Tool for Hereditary Cancer Patients

July 5, 2020

Myriad Launches New GeneSight® Psychotropic Patient Collection Kit

June 30, 2020

Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider

June 14, 2020

Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer

June 3, 2020

Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients

May 28, 2020

Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D.

May 27, 2020

Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer

May 19, 2020

Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer

May 10, 2020

Myriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results

May 4, 2020

Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020

April 27, 2020

Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive Disorder

April 19, 2020

Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic

April 7, 2020

Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC

April 5, 2020

Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer

March 29, 2020

Myriad Announces Board of Directors Leadership Transition

March 22, 2020

Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer

February 10, 2020

Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results

February 5, 2020

Myriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020

January 29, 2020

Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer

January 21, 2020

Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer

January 20, 2020

Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology

January 13, 2020

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer

December 29, 2019

Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes

December 13, 2019

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening

December 3, 2019

Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients

November 20, 2019

Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening

November 10, 2019

Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results

November 3, 2019

Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting

October 31, 2019

Myriad to Announce Fiscal First-Quarter 2020 Financial Results on November 4, 2019

October 29, 2019

Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting

October 27, 2019

FDA Approves Myriad’s myChoice® CDx Test to Help Identify Women Eligible for Treatment with Zejula® in Late-line Ovarian Cancer

October 22, 2019

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience

October 20, 2019

Myriad Genetics Expands Board of Directors with Two Additional Members

September 24, 2019

Myriad Announces Research Collaboration with University of Leeds

September 15, 2019

Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test

April 8, 2019

Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership

April 3, 2019

← Newer news releases

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 48 decks. Every deck is listed under its year.